Hospital
Southern Illinois Hospital Services
Southern Illinois Hospital Services was paid $5.45M by Medicaid between Jan 2018 and Feb 2024, across 153 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 74% of everything it billed.
33Billing provider infoSOUTHERN ILLINOIS HOSPITAL SERVICES
HERRIN, IL 62948
HERRIN, IL 62948
33aNPI1528158573assigned 10/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.45M
24GClaims179,526
24DCodes billed153
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other General Acute Care Hospital providers in Illinois
Rank by total paid#5 of 129
Median peer was paid$547K
This provider vs. median10.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,442 | $1.93M | |
| 2019 | 86,108 | $2.65M | |
| 2020 | 31,715 | $875K | |
| 2022 | 13 | $975.00 | |
| 2024incomplete | 248 | $1K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 74% | 42,699 | 6,166 | $4.03M |
| 97162 | 6.1% | 2,889 | 1,809 | $334K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 2.3% | 6,962 | 1,256 | $128K |
| 97010 | 1.7% | 8,666 | 1,449 | $90K | |
| 97161 | 1.6% | 757 | 404 | $85K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 541 | 215 | $80K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,688 | 5,777 | $45K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 783 | 730 | $45K |
| 80053 | Comprehensive metabolic panel | <1% | 12,721 | 10,646 | $44K |
| 97163 | <1% | 387 | 228 | $43K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,797 | 1,496 | $43K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 457 | 343 | $41K |
141 more codes
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 319 | $29K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 807 | $28K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,192 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,919 | $26K |
| 87522 | Neg quan hep c or qual rna | <1% | 630 | $25K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 439 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,052 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 393 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 630 | $12K |
| 87507 | <1% | 81 | $12K | |
| 72100 | <1% | 940 | $10K | |
| 87902 | <1% | 79 | $9K | |
| 80061 | Lipid panel | <1% | 6,430 | $9K |
| 73630 | <1% | 825 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,822 | $8K |
| 73030 | <1% | 700 | $8K | |
| 73610 | <1% | 509 | $8K | |
| 84403 | <1% | 535 | $8K | |
| 87800 | <1% | 994 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,779 | $7K |
| 80074 | <1% | 576 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,029 | $6K |
| 82607 | <1% | 1,997 | $6K | |
| 85610 | <1% | 2,642 | $6K | |
| 84425 | <1% | 821 | $5K | |
| 83970 | <1% | 518 | $5K | |
| 74018 | <1% | 644 | $5K | |
| 73560 | <1% | 591 | $5K | |
| 73502 | <1% | 365 | $5K | |
| 84439 | <1% | 2,894 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 565 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,217 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 544 | $4K |
| 73130 | <1% | 421 | $4K | |
| 73110 | <1% | 309 | $4K | |
| 87536 | <1% | 72 | $4K | |
| 87581 | <1% | 539 | $3K | |
| 87486 | <1% | 539 | $3K | |
| 73562 | <1% | 292 | $3K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,196 | $3K |
| 97166 | <1% | 343 | $3K | |
| 86038 | <1% | 351 | $3K | |
| 81003 | <1% | 4,367 | $3K | |
| 72040 | <1% | 378 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 186 | $3K |
| 87186 | <1% | 744 | $3K | |
| 82746 | <1% | 923 | $3K | |
| 82728 | <1% | 1,403 | $2K | |
| 83550 | <1% | 1,020 | $2K | |
| 83540 | <1% | 1,412 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 300 | $2K |
| 83735 | <1% | 1,162 | $2K | |
| 87493 | <1% | 159 | $2K | |
| 83655 | <1% | 179 | $2K | |
| 83516 | <1% | 382 | $2K | |
| 84270 | <1% | 229 | $1K | |
| 87338 | <1% | 111 | $1K | |
| 84702 | <1% | 387 | $1K | |
| 87077 | <1% | 395 | $985.38 | |
| 85651 | <1% | 937 | $984.86 | |
| 82043 | <1% | 1,219 | $972.42 | |
| 86039 | <1% | 170 | $937.61 | |
| 84481 | <1% | 470 | $793.01 | |
| 86803 | <1% | 211 | $763.73 | |
| 83883 | <1% | 164 | $757.20 | |
| 83721 | <1% | 602 | $737.33 | |
| 87340 | <1% | 338 | $736.56 | |
| 72070 | <1% | 140 | $710.81 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 23 | $699.20 |
| 82565 | <1% | 409 | $661.23 | |
| 84295 | <1% | 331 | $549.71 | |
| 86140 | <1% | 741 | $527.12 | |
| 97167 | <1% | 59 | $509.95 | |
| 86480 | <1% | 18 | $505.50 | |
| 86617 | <1% | 16 | $491.36 | |
| 83690 | <1% | 374 | $477.96 | |
| 84100 | <1% | 380 | $477.54 | |
| 84146 | <1% | 127 | $476.69 | |
| 84153 | <1% | 124 | $430.36 | |
| 87070 | <1% | 260 | $420.02 | |
| 80164 | <1% | 120 | $409.48 | |
| 84550 | <1% | 511 | $401.73 | |
| 84132 | <1% | 371 | $395.04 | |
| 82977 | <1% | 306 | $391.88 | |
| 97165 | <1% | 47 | $354.25 | |
| 84520 | <1% | 342 | $321.50 | |
| 82105 | <1% | 66 | $304.06 | |
| 71100 | <1% | 22 | $284.45 | |
| 80076 | <1% | 136 | $249.47 | |
| 86592 | <1% | 342 | $247.75 | |
| 84207 | <1% | 76 | $245.28 | |
| 86704 | <1% | 63 | $244.48 | |
| 86376 | <1% | 91 | $233.82 | |
| 86431 | <1% | 148 | $225.43 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,736 | $223.66 |
| 72110 | <1% | 12 | $221.28 | |
| 83001 | <1% | 32 | $167.99 | |
| 82248 | <1% | 171 | $147.73 | |
| 82150 | <1% | 131 | $127.25 | |
| 73080 | <1% | 13 | $125.52 | |
| 87899 | <1% | 12 | $115.56 | |
| 86850 | <1% | 78 | $112.43 | |
| 83002 | <1% | 41 | $103.44 | |
| 82274 | <1% | 27 | $102.27 | |
| 83880 | <1% | 26 | $93.99 | |
| 87045 | <1% | 34 | $83.86 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $83.85 |
| 82247 | <1% | 40 | $81.57 | |
| 85018 | <1% | 121 | $81.46 | |
| 86901 | <1% | 79 | $80.21 | |
| 82310 | <1% | 28 | $72.49 | |
| 86900 | <1% | 79 | $59.56 | |
| 86708 | <1% | 32 | $55.74 | |
| 82550 | <1% | 62 | $50.32 | |
| 84450 | <1% | 35 | $49.51 | |
| 84075 | <1% | 31 | $48.80 | |
| 82040 | <1% | 31 | $43.80 | |
| 82374 | <1% | 17 | $37.36 | |
| 84155 | <1% | 32 | $36.00 | |
| 84460 | <1% | 22 | $35.28 | |
| 86308 | <1% | 16 | $35.04 | |
| 87081 | <1% | 12 | $31.13 | |
| 82670 | <1% | 19 | $29.80 | |
| 84480 | <1% | 20 | $29.57 | |
| 86430 | <1% | 30 | $27.18 | |
| 82947 | <1% | 20 | $26.04 | |
| 87209 | <1% | 18 | $21.99 | |
| 82652 | <1% | 19 | $15.64 | |
| 87177 | <1% | 18 | $14.04 | |
| 87205 | <1% | 15 | $10.20 | |
| 82272 | <1% | 13 | $10.00 | |
| 84446 | <1% | 13 | $4.32 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 409 | $0.00 |
| G8986 | Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 168 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 575 | $0.00 |
| 86317 | 0% | 18 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 512 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,470 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 1,602 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,206 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 1,038 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARTKE, SHANNON (CORPORATE DIRECTOR OF PATIENT FINAN)
| Provider | Location | Paid |
|---|---|---|
| Southern Illinois Hospital Services | Carbondale, IL | $1.68M |
| Southern Illinois Hospital Services | Murphysboro, IL | $1.00M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.